GLP-1 stimulates insulin secretion, suppresses glucagon release, and slows gastric emptying, which collectively help lower blood glucose levels and reduce appetite
These elevated hormone levels then contribute to reducing visceral fat (fat around organs), Key uses and benefits: Reduction of visceral fat (VAT): Tesamorelin is specifically approved to treat excess abdominal fat in HIV-infected patients with lipodystrophy
Stomach problems, sometimes severe, have been reported in people who use Wegovy
The ultimate goal is to generate clinical evidence that leads to official changes in treatment guidelines, ensuring that injection frequency is based on patient-reported symptoms and individual clinical response, rather than solely on national blanket protocols
Gemcitabine: metabolism, mechanisms of action, and self-potentiation